Lidoflazine

Lidoflazine is a piperazine calcium channel blocker. It is a coronary vasodilator with some antiarrhythmic action.[1] Lidoflazine was discovered at Janssen Pharmaceutica in 1964.

Lidoflazine
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
IUPAC name
  • 2-[4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl]-N-(2,6-dimethylphenyl)acetamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.020.285
Chemical and physical data
FormulaC30H35F2N3O
Molar mass491.627 g·mol−1
3D model (JSmol)
Melting point159 to 161 °C (318 to 322 °F)
Solubility in waterAlmost insoluble in water(<0.01%); Very soluble in chloroform(>50%); mg/mL (20 °C)
SMILES
  • CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
InChI
  • InChI=1S/C30H35F2N3O/c1-22-5-3-6-23(2)30(22)33-29(36)21-35-19-17-34(18-20-35)16-4-7-28(24-8-12-26(31)13-9-24)25-10-14-27(32)15-11-25/h3,5-6,8-15,28H,4,7,16-21H2,1-2H3,(H,33,36) N
  • Key:ZBIAKUMOEKILTF-UHFFFAOYSA-N N
 NY (what is this?)  (verify)

Physical properties

Solubility at room temperature

Extracted from[1]

Solvent 0.01

N

 0.1

N

 % pH  % pH
Hydrochloric Acid 0.4 3.0 0.7 1.9
Tartaric Acid 0.3 3.1 1.0 2.5
Citric Acid 0.3 3.1 0.5 2.5
Lactic Acid 0.2 3.4 0.7 2.9
Acetic Acid 0.1 3.5 0.4 3.8

Synthesis

Compare for Ranolazine.

Thieme Patent:[2] alternate preparation of #3:[3]

Alkylation of N-carbethoxypiperazine [120-43-4] (1) with 1-[4-chloro-1-(4-fluorophenyl)butyl]-4-fluorobenzene [3312-04-7] (2) gives CID:12679861 (3). Deprotection of which afforded 1-[4,4-bis(4-fluorophenyl)butyl]piperazine [5631-35-6]. Acylation of 2,6-xylidine (4) with chloroacetyl chloride (5) gives N-chloroacetyl-2,6-xylidine [1131-01-7] (6). The convergent synthesis between the above two counterparts completed the synthesis of lidoflazine (7).

References
  1. Schaper WK, Xhoneux R, Jageneau AH, Janssen PA (May 1966). "The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator". The Journal of Pharmacology and Experimental Therapeutics. 152 (2): 265–74. PMID 5944369.
  2. NL6507312 idem Hermans Hubert Karel Frans, Schaper Wolfgang Karl-Adolf, U.S. Patent 3,267,104 (1966 to Janssen Pharmaceutica Nv).
  3. Anders K. Bjork & Erik G. Christensson, WO 1983001950 (to Pharmacia and Upjohn Animal Health AB).

Further reading
  • Schaper WK, Xhonneux R, Jageneau AH (November 1965). "Stimulation of the coronary collateral circulation by lidoflazine (R 7904)". Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie. 252 (1): 1–8. doi:10.1007/bf00246424. PMID 4222721. S2CID 31959581.

[1]

  1. Zhou, Ping-Zheng; Babcock, Joseph; Liu, Lian-Qing; Li, Min; Gao, Zhao-Bing (2011). "Activation of human ether-a-go-go related gene (HERG) potassium channels by small molecules". Acta Pharmacologica Sinica. 32 (6): 781–788. doi:10.1038/aps.2011.70. PMC 4085723. PMID 21623390.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.